The present disclosure relates to the technical field of medicines, and in particular relates to the use of
nitazoxanide and a pharmaceutically acceptable salt thereof in the preparation of an anti-adamantinomatous craniopharyngioma
drug. Provided in the present disclosure is the use of
nitazoxanide and a pharmaceutically acceptable salt thereof in the preparation of an anti-adamantinomatous craniopharyngioma
drug.
Nitazoxanide and the pharmaceutically acceptable salt thereof are capable of inhibiting the proliferation and
colony formation ability of adamantinomatous craniopharyngioma organoids by means of promoting the degradation of a β-
catenin, are targeted drugs capable of effectively blocking an activation pathway of the β-
catenin, have good therapeutic
efficacy and application prospects for adamantinomatous craniopharyngioma, and solve the problem of lack of targeted drugs for treating adamantinomatous craniopharyngioma.